Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640428 | 0.77 | — | — | |
| SCHEMBL14426373 | 0.64 | — | — | |
| SCHEMBL27796211 | 0.61 | — | — | |
| SCHEMBL5599706 | 0.59 | — | — | |
| SCHEMBL10629784 | 0.58 | — | — | |
| SCHEMBL27143998 | 0.57 | TLR4 (0.33) | — | |
| SCHEMBL6788944 | 0.54 | — | — | |
| SCHEMBL28165752 | 0.54 | SLC18A3 (0.35) | GABRA1GABRG2GABRB3 | |
| SCHEMBL28399280 | 0.53 | — | — | |
| SCHEMBL13829368 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475288-B1 | PROCESS FOR THE PREPARATION OF HIGH-PURITY PRASUGREL | RICHTER GEDEON NYRT (HU) | 2021-11-03 | — | — | EP | claimed |
| EP-2570417-B1 | THIENOPYRIDINE ESTER DERIVATIVE CONTAINING NITRILE, PREPARATION METHOD, USE AND COMPOSITION THEREOF | TIANJIN INST PHARM RESEARCH (CN) | 2015-05-13 | — | — | EP | claimed |
| US-20130274284-A1 | PREPARATION OF PRASUGREL HYDROCHLORIDE | DR. REDDY'S LABORATORIES, INC. (US) | 2013-10-17 | — | — | US | claimed |
| EP-2601200-A2 | PREPARATION OF PRASUGREL HYDROCHLORIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2013-06-12 | — | — | EP | claimed |
| EP-2588483-A1 | IMPROVED PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság (HU) | 2013-05-08 | — | — | EP | claimed |
| US-20130072521-A1 | THIENOPYRIDINE ESTER DERIVATIVE CONTAINING CYANO GROUP, PREPARATION METHOD, USE AND COMPOSITION THEREOF | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2013-03-21 | — | — | US | claimed |
| EP-2570417-A1 | THIENOPYRIDINE ESTER DERIVATIVE CONTAINING NITRILE, PREPARATION METHOD, USE AND COMPOSITION THEREOF | Tianjin Institute Of Pharmaceutical Research (CN) | 2013-03-20 | — | — | EP | claimed |
| US-20130030183-A1 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2013-01-31 | — | — | US | claimed |
| EP-2516447-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | Egis Gyógyszergyár Nyilvánosan Müködö Részvénytársaság (HU) | 2012-10-31 | — | — | EP | claimed |
| EP-2499147-A2 | IMPROVED PROCESSES FOR PREPARING PRASUGREL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEROEOF | MSN Laboratories Limited (IN) | 2012-09-19 | — | — | EP | claimed |
| WO-2010070677-A2 | A PROCESS FOR THE PREPARATION OF PRASUGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | GLENMARK GENERICS LIMITED (IN) | 2010-06-24 | — | — | WO | claimed |
| WO-2009066326-A2 | IMPROVED PROCESS FOR THE PREPARATION OF PRASUGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | WO | claimed |
| EP-0785205-B1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES (JP) | 2002-04-17 | — | — | EP | claimed |
| US-5874581-A | CHEMICAL INTERMEDIATE OF AN ANTIPLATELET MEDICINE AND AN ELASTASE INHIBITOR; REACTING A HALOSILANE AND A 2-OXO-4,5,6,7 -TETRAHYDROTHIENO(3,2-C)PYRIDINE IN THE PRESENCE OF A TERTIARY AMINE | UBE INDUSTRIES, LTD. (JP) | 1999-02-23 | — | — | US | claimed |
| EP-0785205-A1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1997-07-23 | — | — | EP | claimed |
| EP-0069001-B1 | PROCESS FOR THE PREPARATION OF 5,6,7,7A-TETRAHYDRO-4H-THIENO (3,2-C) PYRIDIN-2-ONE DERIVATIVES | ELF SANOFI (FR) | 1985-04-17 | — | — | EP | claimed |
| US-4500534-A | Thieno-pyridinone derivatives, process for its preparation, and anti-blood-platelet and anti-thrombotic applications thereof | SANOFI, S.A. (FR) | 1985-02-19 | — | — | US | claimed |
| EP-0054442-B1 | THIENOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | ELF SANOFI (FR) | 1984-08-29 | — | — | EP | claimed |
| US-4458074-A | Process for the preparation of 5,6,7,7a-tetrahydro-4H-thieno[3,2-c]pyridin-2-ones | SANOFI (FR) | 1984-07-03 | — | — | US | claimed |
| EP-0053949-B1 | PROCESS FOR THE PREPARATION OF 5,6,7,7A-4H-TETRAHYDROTHIENO (3,2-C)PYRIDIN-2-ONES | SANOFI S.A. (FR) | 1983-12-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274284-A1 | PREPARATION OF PRASUGREL HYDROCHLORIDE | PFKP, PF4, PTAFR | GABRA1 1310/4885GABRG2 1388/4885GABRB3 2459/4885 |
| US-20130030183-A1 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | CYP3A5, CYP2C19, CYP4B1 | GABRA1 2849/4885GABRG2 3686/4885GABRB3 3367/4885 |
| US-20130072521-A1 | THIENOPYRIDINE ESTER DERIVATIVE CONTAINING CYANO GROUP, PREPARATION METHOD, USE AND COMPOSITION THEREOF | PTGIS, TNNI3, PTGIR | GABRA1 932/4885GABRG2 1670/4885GABRB3 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.